Human Chorionic Gonadotropin (HCG)
PharmaceuticalThe medical score is slightly higher than the community score, as clinical studies demonstrate clearly positive evidence for approved indications (ART, hypogonadism) [s6, s8, s9], while the community primarily evaluates off-label applications and reports more side effects and uncertainties in that context [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
HCG is a prescription peptide hormone with solid clinical evidence for female infertility treatment, hypogonadotropic hypogonadism, and cryptorchidism. As a TRT adjunct, controlled studies confirm it preserves testicular function and spermatogenesis at 250–500 IU 2–3×/week. Its use for weight loss is definitively debunked by meta-analysis. Off-label use (PCT, bodybuilding) carries real risks — estrogen elevation, Leydig cell desensitization at high chronic doses, and serious quality concerns when sourced without a prescription.
Description
Prescription peptide hormone with LH-like activity; medically used for female infertility, hypogonadism, and cryptorchidism [s1, s2].
Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone physiologically produced by the syncytiotrophoblast of the placenta [s1]. It is classified into four biologically distinct isoforms produced by different cell types [s1]. HCG binds to the LH/CG receptor and functions like pituitary luteinizing hormone (LH), but has a significantly longer half-life of 12–36 hours compared to ~90 minutes for endogenous LH [s2, s3]. In early pregnancy, HCG maintains the corpus luteum and stimulates progesterone production until the placenta can assume this function [s4, s5]. Detection of beta-HCG in blood or urine is considered the most important early indicator of pregnancy [s4]. Medical indications include: 1. Female infertility: Triggering final follicular maturation and ovulation in assisted reproductive technologies (ART); approved as Ovitrelle (recombinant) and Pregnyl (urinary hCG) [s6, s7]. 2. Male hypogonadism (hypogonadotropic type): Stimulation of Leydig cells for testosterone production and maintenance of spermatogenesis [s8, s9]. 3. Cryptorchidism (undescended testes) in childhood: Hormonal induction of testicular descent prior to surgical therapy [s10, s11]. 4. Tumor marker: Beta-HCG is used for diagnosis and monitoring of testicular germ cell tumors and trophoblastic diseases [s15, s16]. In bodybuilding and hormone optimization communities, HCG is used off-label to maintain testicular function during testosterone replacement therapy (TRT) and for post-cycle therapy (PCT) following anabolic steroid use [c1, c2]. This application is not medically approved and carries specific risks [s9, s12]. The use of HCG for weight loss (Simeons protocol) has been classified as ineffective by multiple clinical studies and a meta-analysis; the German Nutrition Society (DGE) and the...
Legal Status (DE)
HCG is a prescription-only medication in Germany (§ 48 AMG). Approved preparations include Pregnyl (urinary hCG) and Ovitrelle (recombinant choriogonadotropin alfa), among others. Dispensing without a prescription is not permitted. Possession of non-approved or non-prescribed HCG preparations may have legal consequences. HCG-containing dietary supplements are not marketable under German and EU law. In the United States, compounding of HCG by pharmacies was prohibited as of March 23, 2020 [s13, s14].
Mechanism of Action
HCG binds with high affinity to the LH/CG receptor (LHCGR), which is expressed in the gonads and other tissues [s2, s3]. In the testes, receptor binding activates adenylate cyclase, increases intracellular cAMP levels, and thereby stimulates cholesterol transport into the mitochondria of Leydig cells. This initiates the steroidogenic cascade leading to testosterone synthesis [s2]. In the ovary, HCG induces luteinization of the preovulatory follicle, triggers ovulation, and supports corpus luteum function with consequent progesterone production [s6, s7]. Compared to endogenous LH, HCG exhibits approximately 10-fold higher receptor affinity and a markedly prolonged half-life (12–36 h vs. ~90 min for LH), which can lead to desensitization of Leydig cells with prolonged use [s2, s3]. HCG also suppresses endogenous GnRH secretion via negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, resulting in cessation of pituitary LH release [s1]. When used as a PCT agent, HCG is intended to reactivate Leydig cell function suppressed by exogenous androgens; however, excessive or prolonged HCG administration can paradoxically cause desensitization and delay recovery of the endogenous HPG axis [s12].
Dosing
Ovulationsauslösung (ART)
- Dose
- 250 µg choriogonadotropin alfa (Ovitrelle) or 5,000–10,000 IU urinary hCG
- Frequency
- einmalige Injektion
- Route
- injektion-subkutan
- Duration
- einmalig
- Timing
- 34–36 hours before planned follicle retrieval
- With food
- optional
Hypogonadotroper Hypogonadismus (Mann)
- Dose
- 1,000–3,000 IU
- Frequency
- 2–3× pro Woche
- Route
- injektion-subkutan
- Duration
- Langzeittherapie, individuell
- Timing
- Maintain equal intervals between injections
- With food
- optional
TRT-Begleittherapie (Erhalt der Spermatogenese)
- Dose
- 250–500 IU
- Frequency
- 2–3× pro Woche
- Route
- injektion-subkutan
- Duration
- parallel zur TRT
- Timing
- Evenly distributed throughout the week
- With food
- optional
Kryptorchismus (Kinder 4–9 Jahre)
- Dose
- 1,500–4,500 IU
- Frequency
- 3× pro Woche für 4–6 Wochen
- Route
- injektion-intramuskulär
- Duration
- 4–6 Wochen
- Timing
- As prescribed by physician
- With food
- optional
Post-Cycle-Therapy (PCT, off-label)
- Dose
- 500 IU daily
- Frequency
- täglich für 1–2 Wochen
- Route
- injektion-subkutan
- Duration
- 1–2 Wochen vor SERM-Beginn
- Timing
- Prior to initiation of clomiphene or tamoxifen
- With food
- optional
For men on TRT, a maximum dose of 500 IU 3×/week is considered sufficient to normalize intratesticular testosterone (ITT); higher doses further increase testosterone but do not additionally improve spermatogenesis and increase the risk of desensitization [s9]. In women, the maximum dose is determined by the ART protocol (max. 10,000 IU urinary hCG for ovulation induction) [s6].
Reconstituted HCG solutions require refrigeration (2–8 °C) and should be used within 30 days. Off-label use (PCT, bodybuilding) without a medical prescription is not legal in Germany. Homeopathic HCG preparations (e.g., HCG C30) contain no active hormone and are clinically ineffective [s18].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Ovarielles Überstimulationssyndrom (OHSS) bei Frauen HCG is the primary triggering hormone of OHSS. Severe cases can cause pleural effusion, renal insufficiency, and life-threatening thromboembolism [s19, s20]. | gelegentlich | schwer |
| Thromboembolische Ereignisse (TVT, Lungenembolie) Increased risk in OHSS and pregnancy; hemoconcentration and activation of coagulation factors play a role [s19, s20]. | selten | schwer |
| Gynäkomastie und Östrogenanstieg beim Mann HCG stimulates testosterone production, which is partially aromatized to estradiol; high doses increase the risk of gynecomastia [s2, s9]. | gelegentlich | moderat |
| Leydig-Zell-Desensibilisierung bei Langzeitanwendung hoher Dosen Prolonged high HCG doses can lead to reduced responsiveness of Leydig cells to subsequent LH or HCG stimulation [s12]. | gelegentlich | moderat |
| Lokale Injektionsreaktionen (Schmerz, Rötung) Typical reaction with s.c./i.m. injections; usually not clinically significant [s11]. | häufig | leicht |
| Kopfschmerzen, Müdigkeit, Reizbarkeit Hormonally mediated general symptoms, described in clinical studies and prescribing information [s6]. | gelegentlich | leicht |
| Vorzeitige Pubertät (Pubertas praecox) bei Kindern In cryptorchidism treatment, androgen induction may lead to premature pubertal development; therapy should then be discontinued [s11]. | selten | moderat |
| Bauchschmerzen, Übelkeit, Erbrechen (im Rahmen von OHSS) Symptoms of ovarian hyperstimulation; often an early warning sign [s19, s20]. | gelegentlich | moderat |
| Flüssigkeitsretention / Ödeme Androgen-mediated sodium retention; particularly relevant in cardiac disease or renal insufficiency [s11]. | gelegentlich | leicht |
Contraindications
HCG increases testosterone and estrogen levels, which may promote the growth of hormone-sensitive tumors [s11].
HCG is the primary trigger hormone for OHSS; contraindicated in high-risk patients (PCOS, multiple follicles, elevated estradiol) [s19, s20].
In the absence of or non-functional gonadal tissue, HCG cannot exert its effect; LH/FSH are already elevated [s8].
Androgen-induced fluid retention may worsen these conditions; close monitoring or contraindication required [s11].
Possible stimulation of hormone-sensitive pathologies; diagnosis required before initiating therapy [s6].
Anaphylactic reactions possible; HCG is a glycoprotein with immunogenic potential [s6].
Use after established pregnancy only under strict indication; teratogenic data insufficient [s6].
Interactions
Synergistic
The combination of HCG and FSH (75 IU FSH + 3,000 IU HCG 3×/week) is superior to standard therapy for spermatogenesis restoration after TRT [s8].
In PCT protocols, HCG is used before clomiphene to reactivate Leydig cells; SERM then stimulates the HPG axis [s12].
HCG directly stimulates Leydig cells for testosterone production, while enclomiphene activates the HPG axis via the hypothalamus. The combination may accelerate sperm restoration in TRT-induced azoospermia.
Kisspeptin-10 acts upstream at the hypothalamus, stimulating GnRH release, which subsequently triggers LH and FSH secretion. In combination with HCG, both the central HPG axis and peripheral Leydig cells are directly targeted.
Gonadorelin stimulates the pituitary to produce both LH and FSH, whereas HCG only mimics LH action at the testes. Sequential or combined use may more completely preserve spermatogenesis in patients on TRT who desire fertility.
HCG stimulates gonadal steroidogenesis and supports hormonal cascades such as the pregnenolone-DHEA axis. This may synergistically improve overall hormonal balance, energy, and mood.
Caution
Frequently combined to control HCG-induced estrogen elevation in men; uncontrolled use can excessively suppress estrogen and impair bone metabolism [s9].
GnRH agonists may downregulate LH/CG receptor expression and attenuate HCG efficacy; concurrent use only under specialist medical supervision [s2].
Additive effect on gonadal stimulation; increased risk of OHSS with concurrent high-dose administration [s19].
HCG can elevate estrogen levels in men. Calcium-D-glucarate promotes glucuronidation and hepatic excretion of estrogen. Unmonitored combination use could lower estrogen levels excessively, destabilizing hormonal balance.
DIM influences estrogen metabolism by promoting the formation of more favorable estrogen metabolites. When used concomitantly with HCG, which can increase estrogen, the overall estrogen balance should be monitored regularly to avoid excessive estrogen suppression.
Studies
Tier A — High Evidence
Outcome: Restoration of spermatogenesis after TRT using HCG+FSH combination
Effect Size: 3,000 IU HCG + 75 IU FSH 3×/week: superior spermatogenesis recovery vs. HCG alone
Outcome: Change in total motile sperm count (TMSC) under HCG
Effect Size: HCG dose has no significant effect on TMSC improvement (p=0.21); consistency of administration is decisive
Outcome: Triggering of final follicular maturation and ovulation in ART
Effect Size: Ovitrelle 250 µg equivalent to 5,000–10,000 IU urinary HCG
Outcome: Testicular descent in cryptorchidism under HCG therapy
Effect Size: 3 HCG injections equally effective as 10 injections in cryptorchidism
Outcome: Weight loss under HCG diet (Simeons protocol)
Effect Size: No scientific evidence for HCG efficacy in obesity; weight loss attributable to caloric restriction
Tier B — Moderate Evidence
Outcome: Preservation of spermatogenesis under simultaneous TRT + HCG 500 IU 3×/week
Effect Size: Low-dose HCG preserves sperm parameters under TRT
Tier C — Low Evidence
Outcome: Role of beta-HCG as tumor marker in testicular germ cell tumors
Effect Size: Beta-HCG together with AFP diagnostically and prognostically relevant in TGCT
Community Evidence
Top reported benefits
- Preservation of testicular size and function during TRT
- Improvement of sperm parameters after anabolic steroid use
- Positive effect on libido and well-being during TRT
- Effective reactivation of Leydig cells in PCT protocols
Top reported issues
- Estrogen elevation with mood swings and water retention
- Storage issues (loss of potency at room temperature)
- Injection burden and costs
- Desensitization with excessively high or prolonged dosing
- Difficulties obtaining without a prescription
The community repeatedly raises concerns about the risk of Leydig cell desensitization with high continuous doses [c2, c3]. Some users report ineffective or counterfeit preparations when sourced through uncontrolled channels. HCG monotherapy as a TRT alternative is discussed but considered less practical than conventional TRT [c1]. Off-label use for weight loss is largely regarded as ineffective within the community, consistent with the scientific evidence [s17, s18].
Scientific Sources
- Physiology, Chorionic Gonadotropin
Nguyen LT, Kiefer MV, et al. (2023). StatPearls – NCBI BookshelfBPMID:32491594 - Efficacy and safety of human chorionic gonadotropin for treatment of cryptorchidism: A meta-analysis of randomised controlled trials
Wei Y, Wang Y, Han T, et al. (2018). Journal of Paediatrics and Child HealthAPMID:29939470DOI - Human Chorionic Gonadotropin (HCG) – FDA Prescribing Information
FDA / Ferring Pharmaceuticals (2011). FDA Drug LabelALink - Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men
Chua ME, Escusa KG, Luna S, et al. (2013). PMC / Therapeutic Advances in UrologyBLink - Notice to Compounders: Changes that affect compounding as of March 23, 2020
U.S. Food and Drug Administration (2020). FDA.govALink - HCG has been banned by the FDA from compounding pharmacies (March 2020)
Medical Health Institute (2020). medicalhealthinstitute.comCLink - Is Human Chorionic Gonadotropin a Reliable Marker for Testicular Germ Cell Tumor? New Perspectives for a More Accurate Diagnosis
Fiore MG, Lucarelli G, Ditonno P, et al. (2025). Cancers (MDPI)BDOI - Using Human Chorionic Gonadotropin as a Tumor Marker
Stenman UH, Alfthan H, et al. (2021). Clinical Laboratory News (ADLM)BLink - The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen GK, Theeuwen I, Assendelft WJ, et al. (1995). British Journal of Clinical Pharmacology / PMCAPMID:7893292DOI - An unfortunate resurgence of human chorionic gonadotropin use for weight loss
Goodbar NH, Foushee JA, Buster NM, et al. (2013). International Journal of Obesity (Nature)BDOI - Ovarian hyperstimulation syndrome: pathophysiology and prevention
Nastri CO, Ferriani RA, Rocha IA, et al. (2010). Reproductive BioMedicine Online / PMCBPMID:20227355DOI - Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG
Fournier T, Guibourdenche J, Evain-Brion D (2018). Endocrine ReviewsBPMID:29982472DOI - Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline (2023)
ASRM Practice Committee (2023). Fertility and Sterility / ASRMALink - Die HCG-Diät
Deutsche Gesellschaft für Ernährung (DGE) (2022). DGE.deALink - Differenzialdiagnostik und -therapie des männlichen Hypogonadismus
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2021). Arzneiverordnung in der PraxisALink - Frontiers: Comparing the response of triple therapy and conventional treatment in male congenital hypogonadotropic hypogonadism: a randomized controlled trial
Various authors (2026). Frontiers in EndocrinologyADOI - Human Luteinizing Hormone and Chorionic Gonadotropin Display Biased Agonism at the LH and LH/CG Receptors
Tranchant T, Durand G, Gauthier C, et al. (2017). Scientific ReportsCPMID:28465527DOI - Humanes Choriongonadotropin – Physiologische Rolle in der Schwangerschaft
Wikipedia-Autoren (2024). Wikipedia DEDLink - hCG (humanes Choriongonadotropin) – Physiologie und Klinik
DocCheck Flexikon-Autoren (2023). DocCheck FlexikonCLink - Ovitrelle 250 micrograms/0.5 ml – Summary of Product Characteristics (SmPC)
Merck Europe B.V. (2023). European Medicines Agency / emcALink - Ovitrelle – EPAR Product Information
European Medicines Agency (2022). EMA EPARALink - Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone
Brahmbhatt J, Liaw A, Schlegel PN, et al. (2024). Fertility and SterilityADOI - Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data
Krzastek SC, Sharma D, et al. (2025). F&S ReportsBDOI - Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy
Hsieh TC, Pastuszak AW, Hwang K, et al. (2013). Journal of UrologyBPMID:23260550DOI
Community Sources
Storage
Unopened
Store unopened ampoules/prefilled syringes at 2–8 °C (refrigerator); do not freeze. Ovitrelle prefilled syringes may be stored for up to 30 days at a maximum of 25 °C.
Opened
After reconstitution, use immediately or store refrigerated (2–8 °C) for a maximum of 24–30 days, depending on manufacturer instructions. Protect from light.
Notes
HCG is a peptide hormone sensitive to heat, light, and repeated freeze-thaw cycles. Never freeze reconstituted solutions. Community reports confirm frequent loss of potency due to improper storage (room temperature over several days) [c3].